Growth and Fatty Acid Metabolism of Human Breast Cancer (MCF-7) Xenografts in Nude Rats: Impact of Constant Light-induced Nocturnal Melatonin Suppression
Overview
Affiliations
The nocturnal melatonin (MLT) surge is a relevant oncostatic signal for a variety of experimental malignancies. Population studies support the hypothesis that exposure to light at night may represent a new risk factor for breast cancer possibly through the suppression of pineal MLT production and/or circadian disruption. We tested the ability of constant light exposure to suppress MLT production in female nude rats and stimulate the growth of tissue-isolated MCF-7 human breast cancer xenografts via increased tumor linoleic acid (LA) metabolism. Rats maintained on an alternating light/dark cycle (L:D group) exhibited a robust circadian MLT rhythm that was abolished following constant light exposure. During the exposure of animals bearing tissue-isolated human MCF-7 breast cancer xenografts to constant light, the rate of tumor growth markedly increased relative to the L:D group. Tumor LA uptake and its metabolism to the mitogen 13-hydroxyoctadecadienoic acid (13-HODE) were also substantially higher under constant light conditions. This is the first biological evidence for a potential link between constant light exposure and increased human breast oncogenesis involving MLT suppression and stimulation of tumor LA metabolism.
Speckle-Free, Angle-Free, Cavity-Free White Laser with a High Color Rendering Index.
Hou C, Tsui W, Chou R, Hsu C, Feria D, Lin T ACS Appl Mater Interfaces. 2024; 16(9):11489-11496.
PMID: 38393972 PMC: 10921373. DOI: 10.1021/acsami.3c17222.
Dauchy R, Hill S, Blask D Methods Mol Biol. 2022; 2550:477-488.
PMID: 36180715 DOI: 10.1007/978-1-0716-2593-4_46.
15-Lipoxygenase and its metabolites in the pathogenesis of breast cancer: A double-edged sword.
Vaezi M, Safizadeh B, Eghtedari A, Ghorbanhosseini S, Rastegar M, Salimi V Lipids Health Dis. 2021; 20(1):169.
PMID: 34838055 PMC: 8627626. DOI: 10.1186/s12944-021-01599-2.
Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments.
Gonzalez A, Alonso-Gonzalez C, Gonzalez-Gonzalez A, Menendez-Menendez J, Cos S, Martinez-Campa C Cancers (Basel). 2021; 13(13).
PMID: 34209857 PMC: 8268559. DOI: 10.3390/cancers13133263.
Su Z, Zhao B, Gong Z, Peng Y, Bai F, Zheng H Micromachines (Basel). 2021; 12(4).
PMID: 33921533 PMC: 8069560. DOI: 10.3390/mi12040421.